Bile duct cancer is medically known as Cholangiocarcinoma. It refers to cancers that arise in the intrahepatic, perihilar, or distal biliary tree. Although it accounts for only about 3% of ...

The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid ...

If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

Bile duct cancer is classified by location: intrahepatic, perihilar, or distal, influencing symptoms and treatment options. Diagnosis involves blood tests, imaging, endoscopic procedures, and biopsy ...

Cancer is a disease that can be treated more effectively if diagnosed early. However, some types of cancer have mild early symptoms and mimic common health problems. Therefore, the disease is often ...

The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Rachna Shroff, MD, is the associate director of clinical investigations at the U of A Cancer Center and a professor and chief of the division of hematology and oncology at the College of Medicine – ...

The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...